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Introduction {#sec005}
============

Medical therapy is the cornerstone of coronary artery disease (CAD) therapy because coronary revascularization per se does not stop atherosclerosis progression. According to the clinical guidelines for the secondary prevention and risk reduction of CAD, several drugs are strongly recommended to improve outcomes including antiplatelet agents, β-blockers (BB), renin-angiotensin system blockers, and statin \[[@pone.0215811.ref001]--[@pone.0215811.ref002]\]. However, not all patients receive the recommended drugs after coronary revascularization including percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Mark et al. recently reported the performance of secondary prevention after revascularization in the USA \[[@pone.0215811.ref003]\]. They found that patients who receive successful coronary revascularization might not use the recommended medications for several reasons, including a belief that cardiac medications are no longer necessary once coronary stenosis has been treated with a stent or bypass surgery.

The aim of this study is to determine the status and effect of secondary prevention after coronary revascularization in Taiwan by analyzing data from the Taiwan National Health Insurance Research Database (NHIRD).

Materials and methods {#sec006}
=====================

Study patients and design {#sec007}
-------------------------

This population-based cohort study was conducted using data from the Longitudinal Health Insurance Database 2000 (LHID 2000) from the NHIRD of Taiwan ([Fig 1](#pone.0215811.g001){ref-type="fig"}). Taiwan National Health Insurance (NHI) is a single-payer national health insurance program launched on March 1, 1995, that covers 99.9% of all Taiwanese residents. LHID 2000 is a randomly sampled dataset of one million beneficiaries from the year 2000 registry of all NHI enrollees. The registry contains information for approximately 23.75 million individuals, with all registration files and original claims data for reimbursement and academic analysis \[[@pone.0215811.ref004]\]. According to the National Health Research Institutes, no significant differences exist in the age, sex, and healthcare costs between the sampled group and all enrollees in NHI \[[@pone.0215811.ref004]\].

![Flow chart of the study.\
NHIRD, National Health Insurance Research Database; LHID, Longitudinal Health Insurance database.](pone.0215811.g001){#pone.0215811.g001}

The patient data were analyzed from the database, in which the international classification of disease-9 (ICD-9) codes is used to define the corresponding diseases. Patients who underwent CABG or PCI from January 2004 to December 2009 were selected for inclusion in the analysis. The prescriptions after the procedures were assessed to determine the kinds of drugs prescribed. Utilization of statins, BB, angiotensin converting enzyme inhibitors (ACEI), angiotensin II type 1 receptor blockers (ARB), and antiplatelets (including aspirin and clopidogrel) was determined by analyzing the prescription of these drugs within 3 months after the procedure.

Collection of demographic data {#sec008}
------------------------------

Demographic data and cardiovascular risk factors including age, gender, hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), old myocardial infarction (OMI), chronic obstructive pulmonary disease (COPD), and hyperlipidemia were obtained from the NHIRD. The profiles of prescription drugs including statin, aspirin, clopidogrel, BB, ACEI, and ARB were recorded and analyzed.

The primary endpoints of this study were a composite of major adverse cardiac and cerebrovascular events (MACCE), including all-cause mortality, myocardial infarction (MI) (ICD-9 code: 410) and unstable angina (ICD-9 code: 4111), stroke (ICD-9 code: 436), revascularization either by PCI (ICD-9 codes: 33076B, 33077B, 33078B) or CABG (ICD-9 codes: 68023B, 68024B, 68025B), and hospitalization for heart failure.

Statistical analysis {#sec009}
--------------------

All data were expressed as percentages or means ± standard deviations for continuous variables. Categorical variables were compared between groups using the Chi-square test. Time-to-event analysis and covariates of risk factors were modeled using the Cox proportional hazards model. The follow-up period was recorded starting on the date of diagnosis and ending on the date of the development of different outcomes or at the last observation up to December 31, 2010. Significant variables in univariate analysis were selected for multivariate analysis. A p value \< 0.05 was considered statistically significant. All statistical operations were performed using the SAS software version 9.2 (SAS Institute, Cary, NC, USA).

Ethic statement {#sec010}
---------------

Our study was approved by the Kaohsiung Medical University Chung-Ho Memorial Hospital Institutional Review Board (KMUHIRB-EXEMPT(I)- 20180028). Because all data from NHIRD was anonymous, informed consent was not needed.

Results {#sec011}
=======

The cohort comprised 5544 patients who received coronary revascularization. Among them, 895 underwent CABG and 4649 underwent PCI. The baseline characteristics of both groups are shown in [Table 1](#pone.0215811.t001){ref-type="table"}. Patients who underwent CABG had more comorbidities including DM, hypertension, hyperlipidemia, CKD, and COPD.

10.1371/journal.pone.0215811.t001

###### Baseline characteristics in CABG and PCI groups.

![](pone.0215811.t001){#pone.0215811.t001g}

                                              CABG         PCI           p value
  ------------------------------------------- ------------ ------------- ----------
  Total                                       895          4649          
  Age                                         65.2         66.0          0.0601
  Male (%)                                    680 (75.9)   3367 (72.4)   0.0283
  Diabetes (%)                                434 (48.4)   1785 (38.3)   \<0.0001
  Hypertension (%)                            662 (73.9)   3215 (69.1)   0.0004
  Hyperlipidemia (%)                          382 (42.6)   1643 (35.3)   \<0.0001
  Chronic kidney disease (%)                  104 (11.6)   389 (8.3)     0.0045
  Old myocardial infarction (%)               89 (9.9)     211 (4.5)     \<0.0001
  Chronic obstructive pulmonary disease (%)   124 (13.8)   720 (15.4)    0.2132
  Acute coronary syndrome (%)                 203 (22.7)   1390 (29.9)   \<0.0001
  β-blocker (%)                               382 (42.6)   1996 (42.9)   0.8889
  Antiplatelet (%)                            396 (44.2)   2368 (50.9)   0.0002
  Statin (%)                                  362 (40.4)   1882 (40.4)   0.9845
  ACEI/ARB (%)                                346 (38.6)   2274 (48.9)   \<0.0001
  MACCE at 12 months                          303 (33.9)   1059 (22.8)   \<0.0001
  All-cause mortality                         138 (15.4)   435 (9.4)     \<0.0001

PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers; MACCE, major adverse cardiac and cerebrovascular event

The medications used and the incidence of MACCE at 12 months in both groups are also presented in [Table 1](#pone.0215811.t001){ref-type="table"}. Patients in the CABG group experienced more cardiovascular events at 12 months. There was no statistically significant difference in BB and statins use between the two groups but more patients in the PCI group had taken ACEI/ARB and antiplatelets at the 12th month than patients in the CABG group. Those still taking antiplatelets had more cases of hyperlipidemia and prior PCI but less history of OMI and COPD ([Table 2](#pone.0215811.t002){ref-type="table"}). Those still taking BB had more cases of hypertension, hyperlipidemia, and PTCA history but less COPD ([Table 3](#pone.0215811.t003){ref-type="table"}). Those still taking antiplatelets had more cases of hyperlipidemia but less CKD and COPD ([Table 4](#pone.0215811.t004){ref-type="table"}). Those still taking ACEI/ARB had more cases of diabetes, hypertension, and PCI history but less CKD and CABG ([Table 5](#pone.0215811.t005){ref-type="table"}).

10.1371/journal.pone.0215811.t002

###### Factors associated with antiplatelet use at 12 months.
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                       Antiplatelet Use   No Antiplatelet Use   p value
  -------------------- ------------------ --------------------- ----------
  Total (%)            2764 (49.9)        2780 (50.1)           
  Age                  65.6 ± 11.7        66.3 ± 12.4           0.0499
  Male (%)             2025 (73.3)        2022 (72.7)           0.6570
  Diabetes (%)         1125 (40.7)        1094 (39.4)           0.3052
  Hypertension (%)     1940 (70.2)        1937 (69.7)           0.6777
  Hyperlipidemia (%)   1050 (38.0)        975 (35.1)            0.0241
  CKD (%)              225 (8.1)          253 (9.1)             0.2028
  Old MI (%)           141 (5.1)          159 (5.7)             0.3091
  COPD (%)             387 (14.0)         457 (16.4)            0.0115
  CABG (%)             396 (14.3)         499 (17.9)            0.0002
  PCI (%)              2490 (90.1)        2371 (85.3)           \<0.0001

CKD, chronic kidney disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention

10.1371/journal.pone.0215811.t003

###### Factors associated with β-blocker use at 12 months.
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                       β-blocker Use   No β-blocker Use   p value
  -------------------- --------------- ------------------ ----------
  Total (%)            2378 (42.9)     3166 (57.1)        
  Age                  63.9 ± 11.7     67.4 ± 12.1        \<0.0001
  Male (%)             1756 (73.8)     2291 (72.4)        0.2190
  Diabetes (%)         963 (40.5)      1256 (39.7)        0.5351
  Hypertension (%)     1752 (73.7)     2125 (67.1)        \<0.0001
  Hyperlipidemia (%)   968 (40.7)      1057 (33.4)        \<0.0001
  CKD (%)              194 (8.2)       284 (9.0)          0.2863
  Old MI (%)           125 (5.3)       175 (5.5)          0.6590
  COPD (%)             277(11.6)       567 (17.9)         \<0.0001
  CABG (%)             382(16.1)       513 (16.2)         0.8889
  PCI (%)              2111 (88.8)     2750 (86.9)        0.0321

CKD, chronic kidney disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention

10.1371/journal.pone.0215811.t004

###### Factors associated with statin use at 12 months.
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                       Statin Use    No Statin Use   p value
  -------------------- ------------- --------------- ----------
  Total (%)            2244 (40.5)   3300 (59.5)     
  Age                  63.4 ± 11.6   67.6 ± 12.1     \<0.0001
  Male (%)             1649 (73.5)   2398 (72.7)     0.5006
  Diabetes (%)         899 (40.1)    1320 (40.0)     0.9629
  Hypertension (%)     1544 (68.8)   2333 (70.7)     0.1317
  Hyperlipidemia (%)   1079 (48.1)   946 (28.7)      \<0.0001
  CKD (%)              137 (6.1)     341 (10.3)      \<0.0001
  Old MI (%)           109 (4.9)     284 (8.6)       0.0810
  COPD (%)             271 (12.1)    573 (17.4)      \<0.0001
  CABG (%)             362 (16.1)    533 (16.2)      0.9845
  PCI (%)              1978 (88.1)   2883 (87.4)     0.3842

CKD, chronic kidney disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention

10.1371/journal.pone.0215811.t005

###### Factors associated with ACEI/ARB use at 12 months.
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                       ACEI/ARB Use   No ACEI/ARB Use   p value
  -------------------- -------------- ----------------- ----------
  Total (%)            2620 (47.3)    2924 (52.7)       
  Age                  65.5 ± 11.9    66.2 ± 12.2       0.0214
  Male (%)             1882 (71.8)    2165 (74.0)       0.0642
  Diabetes (%)         1134 (43.3)    1085 (37.1)       \<0.0001
  Hypertension (%)     2005 (76.5)    1872 (64.0)       \<0.0001
  Hyperlipidemia (%)   982 (37.5)     1043 (35.7)       0.1622
  CKD (%)              167 (6.4)      311 (10.6)        \<0.0001
  Old MI (%)           143 (5.5)      157 (5.4)         0.8842
  COPD (%)             395 (15.1)     449 (15.4)        0.7725
  CABG (%)             346 (13.2)     549 (18.8)        \<0.0001
  PCI (%)              2372 (90.5)    2489 (85.1)       \<0.0001

CKD, chronic kidney disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention

Cox regression analysis showed that age, diabetes, CKD, and COPD were risk factors while male sex and statin use were protective factors for the primary endpoints in the PCI group ([Table 6](#pone.0215811.t006){ref-type="table"}). The hazard ratios (95% confidence interval) were 1.03 (1.02--1.04), 1.49 (1.31--1.69), 1.66 (1.39--1.99), 1.19 (1.02--1.39), 0.87 (0.76--0.99), and 0.74 (0.64--0.85), respectively. In the CABG group ([Table 7](#pone.0215811.t007){ref-type="table"}), age, diabetes, and CKD were risk factors and statin use was a protective factor for the primary endpoints. The hazard ratios (95% confidence interval) were 1.03 (1.02--1.04), 1.34 (1.06--1.70), 1.59 (1.16--2.18), and 0.76 (0.58--1.00), respectively.

10.1371/journal.pone.0215811.t006

###### Cox regression analysis in PCI group.

![](pone.0215811.t006){#pone.0215811.t006g}

  variable       HR     lower 95%CI   upper 95%CI   p value
  -------------- ------ ------------- ------------- ----------
  Age            1.03   1.02          1.04          \<0.0001
  Male           0.87   0.76          0.99          0.0347
  Diabetes       1.49   1.31          1.69          \<0.0001
  Hypertension   0.94   0.82          1.09          0.4051
  CKD            1.66   1.39          1.99          \<0.0001
  Old MI         0.80   0.60          1.07          0.1259
  COPD           1.19   1.02          1.39          0.0293
  ACEI/ARB       0.98   0.86          1.12          0.7286
  β-blocker      0.99   0.86          1.13          0.8383
  Statin         0.74   0.64          0.85          \<0.0001
  Antiplatelet   0.89   0.79          1.02          0.0899

PCI, percutaneous coronary intervention; CKD, chronic kidney disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers

10.1371/journal.pone.0215811.t007

###### Cox regression analysis in CABG group.
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  variable       HR     lower 95%CI   upper 95%CI   P-value
  -------------- ------ ------------- ------------- ----------
  Age            1.03   1.02          1.04          \<0.0001
  Male           1.27   0.96          1.68          0.0947
  Diabetes       1.34   1.06          1.70          0.0152
  Hypertension   0.88   0.67          1.16          0.3589
  CKD            1.59   1.16          2.18          0.0042
  Old MI         1.04   0.72          1.50          0.8302
  COPD           1.08   0.80          1.46          0.6291
  ACEI/ARB       1.12   0.88          1.43          0.3635
  β-blocker      0.98   0.75          1.27          0.8577
  Statin         0.76   0.58          1.00          0.0491
  Antiplatelet   0.86   0.68          1.11          0.2440

CABG, coronary artery bypass grafting; CKD, chronic kidney disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers

The trends in prescription changes for these medications after 1 year and during the follow-up years i.e., from 2004 to 2009 were also analyzed (Tables [8](#pone.0215811.t008){ref-type="table"} and [9](#pone.0215811.t009){ref-type="table"}). The use of all medications except antiplatelet increased from the time of discharge to the 12-month follow-up ([Fig 2](#pone.0215811.g002){ref-type="fig"}). Patients were divided into three groups according to the time they received PCI or CABG: 1) 2004--2005, 2) 2006--2007, and 3) 2008--2009. ([Fig 3](#pone.0215811.g003){ref-type="fig"}).

![Trend in prescription changes over 1 year.](pone.0215811.g002){#pone.0215811.g002}

![Trend in prescription changes during the follow-up years.](pone.0215811.g003){#pone.0215811.g003}

10.1371/journal.pone.0215811.t008

###### Trend in prescription changes over 1 year.
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                     Discharge     3 months      12 months
  ------------------ ------------- ------------- -------------
  ACEI/ARB (%)       2169 (39.1)   2549 (45.9)   2620 (47.3)
  β-blocker (%)      1773 (32.0)   2351 (42.4)   2378 (42.9)
  Antiplatelet (%)   4157 (74.9)   4221 (76.1)   2764 (49.9)
  Statin (%)         1811 (32.6)   2155 (38.9)   2244 (40.5)

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers

10.1371/journal.pone.0215811.t009

###### Trend in prescription changes during the follow-up years.
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                     PCI/CABG in 2004--2005 (N = 1531)   PCI/CABG in 2006--2007 (N = 1887)   PCI/CABG in 2008--2009 (N = 2126)
  ------------------ ----------------------------------- ----------------------------------- -----------------------------------
  ACEI/ARB (%)       776 (50.7)                          997 (52.8)                          847 (39.8)
  β-blocker (%)      737 (48.1)                          929 (49.2)                          712 (33.5)
  Antiplatelet (%)   827 (54.0)                          1127 (59.7)                         810 (38.1)
  Statin (%)         617 (40.3)                          859 (45.5)                          768 (36.1)

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers

A total of 573 patients died during the follow-up period. These patients had a significantly lower percentage of medication use compared with the patients who survived ([Table 10](#pone.0215811.t010){ref-type="table"}). We also analyze the use of each medication at discharge and the rate of death and recurrent myocardial infarction during the period of follow-up ([Table 11](#pone.0215811.t011){ref-type="table"}). We found that the rate was higher in the patients who were not taking these drugs at discharge. (20.4% in patients without antiplatelet vs 15.5% in those with antiplatelet, 18.1% in those without ACEI/ARB vs 14.6% in those with ACEI/ARB, 19.0% in those without statin vs 12.0% in those with statin, 18.2% in those without β-blocker vs 13.6% in those with β-blocker)

10.1371/journal.pone.0215811.t010

###### The mortality of patients with and without prescription medication at the end of follow-up.
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                        Death        Live          p value
  -------------- ------ ------------ ------------- ----------
  Total          5544   573 (10.3)   4971 (89.7)   
  ACEI/ARB       2549   146 (25.5)   2403 (48.3)   \<0.0001
  β-blocker      2351   118 (20.6)   2233 (44.9)   \<0.0001
  Antiplatelet   4221   275 (48.0)   3946 (79.4)   \<0.0001
  Statin         2155   86 (15.0)    2069 (41.6)   \<0.0001

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers

10.1371/journal.pone.0215811.t011

###### The rate of death and recurrent myocardial infarction in patients with/without the medication in their prescription at discharge.
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  ---------------------------------------------------------------------------------------------------------------------------------
                 Total\   Antiplatelet -   Antiplatelet +   ACEI/ARB -   ACEI/ARB +   Statin\   Statin\   β-blocker\   β-blocker\
                                                                                      -         +         -            +
  -------------- -------- ---------------- ---------------- ------------ ------------ --------- --------- ------------ ------------
  Total          5544     1387             4156             3375         2169         3733      1811      3771         1773

  Death/Re-MI\   927\     284\             643\             611\         316\         710\      217\      686\         241\
  (%)            (16.7)   (20.4)           (15.5)           (18.1)       (14.6)       (19.0)    (12.0)    (18.2)       (13.6)
  ---------------------------------------------------------------------------------------------------------------------------------

Re-MI, recurrent myocardial infarction; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers

Discussion {#sec012}
==========

There were three major findings in this study. First, evidence-based medicine was still being applied for less than 50% of patients who received revascularization including PCI and CABG at the 12^th^ month in Taiwan. Second, patients who took statin continuously had fewer cardiovascular events in both the PCI and CABG groups. Third, DM and CKD were risk factors for the primary endpoints in both groups.

Possible reasons for the cessation of evidence-based therapies could be inertia on the part of the patients or physicians. Patients might misconceive PCI or CABG as the definitive treatment for CAD and therefore stop taking their medicine. Furthermore, they may think that CAD is no longer severe enough after revascularization to require medication. The prescription rate in our study was relatively low compared with that in studies performed in other countries. One study in the USA reported that around 70% of patients continued to use ACE/ARB, statin, and BB after PCI or CABG \[[@pone.0215811.ref003]\]. Another study reported a medication adherence of 67.3% for antiplatelets, 69.7% for BB, 32.5% for ACEI/ARB, and 61.3% for statin one year after CABG \[[@pone.0215811.ref005]\]. A study in Germany showed the medication use a year after acute MI was 73.7% for aspirin, 72.5% for statin, 70% for ACEI, and 80% for BB \[[@pone.0215811.ref006]\]. There are huge gaps between current guideline recommendations and real-world practice in Taiwan. More work including physician education is needed to encourage the use of evidence-based medicine if no contraindications exist.

The drugs we investigated have been widely demonstrated to have benefits for the secondary prevention of atherosclerotic cardiovascular disease. Aspirin can reduce the risk of cardiovascular death and MI by 25% \[[@pone.0215811.ref007]\]. Dual antiplatelet therapy has also been proven to have more benefits than aspirin alone in patients who received PCI with stent placement \[[@pone.0215811.ref008]\]. ACEI can reduce the rate of cardiovascular events particularly among patients with left ventricular dysfunction, DM, hypertension, and CKD \[[@pone.0215811.ref009]\]. BBs have been proven to be beneficial in patients with left ventricular dysfunction, acute coronary syndrome, or prior MI. Furthermore, BBs also reduces the incidence of postoperative atrial fibrillation in CABG patients. Therefore, current guidelines recommend BBs for all CABG patients at the time of hospital discharge. Statin is the most evidence-based medicine available to treat dyslipidemia and should be prescribed to all patients in the absence of contraindications. The ASCOT-LLA and WOSCOPS trials demonstrate the long-term benefits of lowering LDL-C for the reduction of cardiovascular diseases \[[@pone.0215811.ref010]--[@pone.0215811.ref011]\]. In our study, statin treatment had cardiovascular benefits for both the PCI and CABG groups. Factors associated with lower 12-month statin use including age, CKD, DM, and COPD should be taken into consideration in daily practice.

DM is a strong risk factor for cardiovascular complications as it increases the risk of greater severity and progression of coronary disease and should be treated aggressively. Patients with CKD are at a higher risk for cardiovascular disease, and particular care should be taken to address comorbidities and disease management \[[@pone.0215811.ref012]\]. Patients with COPD are also at risk for cardiovascular events, which may be attributed to increased systemic inflammation. In our study, we found that patients with DM or CKD had a higher risk of further cardiovascular events in both the PCI and CABG groups. COPD was also found to be an independent risk factor for cardiovascular events in the PCI group. Patients with DM or CKD are recognized as a very high-risk group in current guidelines and need to receive intensive treatment to lower their risk for future cardiovascular events \[[@pone.0215811.ref013]\]. A previous study found that the exacerbation of COPD increases the risk of MI and stroke \[[@pone.0215811.ref014]--[@pone.0215811.ref015]\]. Our study provides more evidence of the importance of paying more attention to patients with CKD, DM, and COPD to reduce future cardiovascular events after coronary revascularization.

Patients who died during the follow-up period received much fewer medications than those who survived. One possible reason is that the condition of these patients was not suitable for the medications (e.g., bleeding complications, hypotension, acute kidney injury, etc.), and the doctor stopped the medication prematurely. However, the drugs we investigated have been widely demonstrated to have benefits for the secondary prevention of atherosclerotic cardiovascular disease. Furthermore, the prescription at discharge seems to be important for the patients and has some impact for the clinical outcomes. Every effort should be made to encourage prescription especially before discharge.

This retrospective study has several limitations. First, we lacked sufficient detailed clinical data to explore the reasons why certain medications were not prescribed, such as information on the serum creatinine level, left ventricular function, and LDL level, which could have affected the prescription pattern. Second, our data only showed the drugs prescribed by doctors, but whether the patients actually took the medications remains unknown and this might influence the effect of the drugs on the cardiovascular outcomes. Third, the underlying diseases were determined based on the ICD codes. We may have underestimated the patients' comorbidities for cases in which the doctors did not record the codes. Fourth, the national insurance reimbursement criteria may limit the medications physicians can prescribe to meet the clinical practice guidelines. Fifth, there could be some survivor bias while assessing for medication usage and hazards of cardiac outcomes. However, the drugs we investigated have been widely demonstrated to have benefits for the secondary prevention of atherosclerotic cardiovascular disease. Sixth, the national health insurance only allowed 9-month dual antiplatelet treatment which might partially explain the significant reduction of antiplatelet from 9^th^ month to 12^th^ month.

Conclusions {#sec013}
===========

Much room for improvement in daily practice remains for the secondary prevention of CAD after revascularization in Taiwan. Statin is the most important of 4 ACC/AHA Class I drugs that can improve the outcomes. Physicians should be encouraged to prescribe statin if no contraindication. The benefit of long-term use of 4 ACC/AHA Class I drugs should be educated to all physicians. Furthermore, the control of risk factors including DM, CKD, and COPD is important in Taiwan. Further research is needed to understand the reasons evidence-based medications are not prescribed after CABG or PCI, and to develop appropriate strategies to improve prescription.
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